First human test of AZD4076 for fatty liver begins
NCT ID NCT02612662
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called AZD4076 in 40 healthy men to see if it is safe and how the body processes it. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious liver condition. This is an early, first-in-human trial, so it focused only on safety and drug levels, not on treating the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS (NASH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Brooklyn, Maryland, 21225, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- 10-Year quest to uncover fatty Liver's hidden toll in china
- New ultrasound device could replace costly MRI for liver disease detection
- Diabetes drugs may reverse fatty liver damage in new trial
- Blood tests could spot hidden liver risk in diabetics
- One Breath-Hold MRI could replace liver biopsies for NASH
- New pill shows promise against fatty liver disease in Mid-Stage trial